Should Off-Label Comparators Be Used In HTAs? Swedish Court Investigates
This article was originally published in Scrip
Executive Summary
Should an off-label use of an existing medicine be allowed as a comparator when conducting health technology assessments on new drugs? Some prominent European HTA bodies, like the National Institute for Health and Care Excellence (NICE), are quite happy to include off-label uses in their evaluations, but others, including many in the originator industry, feel such comparisons are not necessarily valid.